REGN REGENERON PHARMACEUTICALS, INC. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$675.19

Period return

-80.32 (-10.63%)

Volume

471.8K

2026-07-21O $672.55 H $678.67 L $666.88 C $675.19MA5 $673.48MA20 $651.84MA60 $656.21MA120 $709.85

6M · 124 barsYahoo Finance · USD2026-01-22 → 2026-07-21

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 07. 30.Highin 9 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2026. 05. 19.LowBUY2 months ago
Canaccord Genuity: Buy
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
BMO Capital: Outperform
US analyst rating / recommendation change.
2026. 05. 19.LowBUY2 months ago
Truist Securities: Buy
US analyst rating / recommendation change.
2026. 05. 18.LowBUY2 months ago
JP Morgan: Overweight
US analyst rating / recommendation change.
2026. 05. 18.LowBUY2 months ago
Piper Sandler: Overweight
US analyst rating / recommendation change.
2026. 05. 18.LowHOLD2 months ago
Wells Fargo: Equal-Weight
US analyst rating / recommendation change.
2026. 05. 18.Low2 months ago
RBC Capital: r Perform
US analyst rating / recommendation change.
2026. 05. 18.MediumHOLD2 months ago
Citigroup: Neutral
US analyst rating / recommendation change.
2026. 05. 18.MediumHOLD2 months ago
Leerink Partners: Market Perform
US analyst rating / recommendation change.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Consensus PT $833.31 · 28 analysts

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 07. 30.	After market close (AMC)	$10.85	—	—	$3.81B	—	Scheduled
FY2026 Q1	2026. 04. 29.	Time TBD	—	$7.27	—	—	$3.03B	Reported
FY2025 Q3	2025. 10. 28.	Time TBD	—	$30.23	—	—	$10.41B	Reported
FY2025 Q2	2025. 08. 01.	Time TBD	—	$18.68	—	—	$6.69B	Reported

#	Institution	Mandate	Shares	Value	Weight	Change	Position
1	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	812,236	$627.57M	0.54%	—	New position
2	TWO SIGMA INVESTMENTS, LP	TWO SIGMA INVESTMENTS, LP	281,151	$217.01M	0.34%	—	New position
3	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	262,527	$202.64M	0.33%	—	New position
4	Point72 Asset Management, L.P.	Point72 Asset Management, L.P.	2,175	$1.68M	0.00%	—	New position

REGENERON PHARMACEUTICALS, INC.리제네론

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats

Date	Firm	Analyst	Action	Rating change	Price target	Report
2026. 05. 19.	Canaccord Genuity	—	Maintain	Buy → Buy	—	Canaccord Genuity: Buy
2026. 05. 19.	BMO Capital	—	Maintain	Outperform → Outperform	—	BMO Capital: Outperform
2026. 05. 19.	Truist Securities	—	Maintain	Buy → Buy	—	Truist Securities: Buy
2026. 05. 18.	JP Morgan	—	Maintain	Overweight → Overweight	—	JP Morgan: Overweight
2026. 05. 18.	Piper Sandler	—	Maintain	Overweight → Overweight	—	Piper Sandler: Overweight
2026. 05. 18.	Wells Fargo	—	Maintain	Equal-Weight → Equal-Weight	—	Wells Fargo: Equal-Weight